Safety and Tolerability of KIO-101 Eye Drops in Healthy Volunteers and Patients with Ocular Surface Disease-A Phase I Study.
Doreen SchmidlNikolaus HommerMartin KallabAndreas SchlatterClemens NadvornikFranz ObermayrStefan SperlEric J DanielsGerhard GarhöferPublished in: Pharmaceutics (2024)
A 12-day treatment regimen with topical KIO-101 eye drops at low and mid doses was safe and well tolerated in both HVs and patients with conjunctival hyperemia. The obtained results point towards an early sign of reduction in conjunctival hyperemia.